Joshua T Brumm Dyne Therapeutics, Inc. (DYN) insider trading activity

Joshua T Brumm is CEO & President of Dyne Therapeutics, Inc.. Currently has a direct ownership of 537,998 shares of DYN, which is worth approximately $12.2 Million. The most recent transaction as insider was on Mar 11, 2024, when has been sold 66,387 shares (Common Stock) at a price of $25.89 per share, resulting in proceeds of $1,718,759. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 538K

0% 3M change

0% 12M change

Total Value Held $12.2 Million

Joshua T Brumm Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 11 2024	SELL Open market or private sale	$1,718,759 $25.89 p/Share	66,387 Reduced 10.98%	537,998 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	$277,000 $5.54 p/Share	50,000 Added 7.64%	604,385 Common Stock
Mar 08 2024	SELL Open market or private sale	$9,617,689 $26.47 p/Share	363,343 Reduced 39.59%	554,385 Common Stock
Mar 08 2024	BUY Exercise of conversion of derivative security	$2,012,920 $5.54 p/Share	363,343 Added 28.36%	917,728 Common Stock
Mar 07 2024	SELL Open market or private sale	$234,873 $25.85 p/Share	9,086 Reduced 1.61%	554,385 Common Stock
Mar 01 2024	SELL Open market or private sale	$2,745,588 $29.06 p/Share	94,480 Reduced 14.36%	563,471 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$523,419 $5.54 p/Share	94,480 Added 12.56%	657,951 Common Stock
Feb 29 2024	SELL Open market or private sale	$151,800 $27.5 p/Share	5,520 Reduced 0.97%	563,471 Common Stock
Feb 29 2024	BUY Exercise of conversion of derivative security	$30,580 $5.54 p/Share	5,520 Added 0.96%	568,991 Common Stock
Jan 29 2024	SELL Bona fide gift	-	21,500 Reduced 3.68%	563,471 Common Stock
Jan 04 2024	SELL Open market or private sale	$4,090,993 $18.72 p/Share	218,536 Reduced 27.2%	584,971 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	$718,983 $3.29 p/Share	218,536 Added 21.38%	803,507 Common Stock
Jan 03 2024	SELL Open market or private sale	$987,320 $19.29 p/Share	51,183 Reduced 8.05%	584,971 Common Stock
Jan 03 2024	BUY Exercise of conversion of derivative security	$52,718 $1.03 p/Share	51,183 Added 7.45%	636,154 Common Stock
Dec 11 2023	SELL Open market or private sale	$81,311 $10.72 p/Share	7,585 Reduced 1.28%	584,971 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	-	358,877 Added 37.72%	592,556 Common Stock
Sep 18 2023	SELL Open market or private sale	$113,221 $9.41 p/Share	12,032 Reduced 4.9%	233,679 Common Stock
Sep 12 2023	SELL Open market or private sale	$79,865 $10.41 p/Share	7,672 Reduced 3.03%	245,711 Common Stock
Jun 12 2023	SELL Open market or private sale	$2,367,502 $12.61 p/Share	187,748 Reduced 42.56%	253,383 Common Stock
Jun 12 2023	BUY Exercise of conversion of derivative security	$176,500 $1.03 p/Share	171,360 Added 27.98%	441,131 Common Stock
Jun 09 2023	SELL Open market or private sale	$1,021,603 $13.34 p/Share	76,582 Reduced 22.11%	269,771 Common Stock
Jun 09 2023	BUY Exercise of conversion of derivative security	$78,879 $1.03 p/Share	76,582 Added 18.11%	346,353 Common Stock
Jun 08 2023	SELL Open market or private sale	$811,910 $13.31 p/Share	61,000 Reduced 18.44%	269,771 Common Stock
Jun 08 2023	SELL Bona fide gift	-	21,800 Reduced 6.76%	300,683 Common Stock
Jun 08 2023	BUY Exercise of conversion of derivative security	$30,990 $1.03 p/Share	30,088 Added 8.34%	330,771 Common Stock

JTB

Joshua T Brumm

CEO & President

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DYN shares.

Notify only if

Value

Insider Trading

Get notified when an Dyne Therapeutics, Inc. insider buys or sells DYN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Dyne Therapeutics, Inc.

Track Activities on DYN

Account